

Signaling cascades for delta-opioid receptor-mediated inhibition of GABA synaptic transmission and behavioral antinociception

Zhi Zhang and Zhizhong Z. Pan

Department of Anesthesiology and Pain Medicine

The University of Texas MD Anderson Cancer Center

1515 Holcombe Boulevard

Houston, TX 77030

Running title: Delta-opioid receptor signaling

Corresponding author: Zhizhong Z. Pan

Department of Anesthesiology and Pain Medicine

The University of Texas MD Anderson Cancer Center

1515 Holcombe Boulevard, Unit 110

Houston, TX 77030

Tel: (713) 792-5559 Fax: (713) 745-3040

E-mail: zzpan@mdanderson.org

Number of text pages: 31

Number of Figures: 7

Number of Tables: 0

Number of references: 37

Number of words: Abstract 244

Introduction 600

Discussion 1165

Abbreviations:

AA, arachidonic acid; DOR, delta-opioid receptor; COX, cyclooxygenase; GPCR, G protein-coupled receptor; IPSCs, inhibitory post-synaptic currents; LOX, lipoxygenase; MOR, mu-opioid receptor; NRM, nucleus raphe magnus; PKA, protein kinase A; PLA2, phospholipase A2.

Abstract

Membrane trafficking of the delta-opioid receptor (DOR) from intracellular compartments to plasma membrane in central neurons, induced by various pathological conditions such as chronic opioid exposure, represents unique receptor plasticity involved in the mechanisms of chronic opioid effects in opioid addiction and opioid treatment of chronic pain. However, the signaling pathways coupled to the newly emerged functional DOR in central neurons are largely unknown at present. In this study, we investigated the signaling cascades of chronic morphine-induced DOR for its cellular and behavioral effects in neurons of the rat brainstem nucleus raphe magnus (NRM), a key supraspinal site for opioid analgesia. We found that, among the three phospholipase A2 (PLA2)-regulated arachidonic acid (AA) metabolic pathways of lipoxygenase, cyclooxygenase and epoxygenase, 12-lipoxygenase of the lipoxygenase pathway primarily mediated DOR inhibition of GABA synaptic transmission, as inhibitors of 12-lipoxygenase as well as lipoxygenases and PLA2 largely blocked the DOR- or AA-induced GABA inhibition in NRM neurons in brainstem slices *in vitro*. Blockade of the epoxygenase pathway was ineffective whereas blocking either 5-lipoxygenase of the lipoxygenase pathway or the cyclooxygenase pathway enhanced the DOR-mediated GABA inhibition. Behaviorally in rats *in vivo*, NRM infusion of 12-lipoxygenase inhibitors significantly reduced DOR-induced antinociceptive effect while inhibitors of 5-lipoxygenase and cyclooxygenase augmented the DOR antinociception. These findings suggest the PLA2-AA-12-lipoxygenase pathway as a primary signaling cascade for DOR-mediated analgesia through inhibition of GABA neurotransmission and indicate potential therapeutic benefits of combining 5-lipoxygenase and cyclooxygenase inhibitors for maximal pain inhibition.

Introduction

Opioids are commonly used for treating chronic pain, but they also have strong reinforcing effects that induce addiction after prolonged exposure (Woolf and Hashmi, 2004). Opioid effects are mediated mostly by three classic opioid receptor subtypes: mu-opioid receptor (MOR), delta-opioid receptor (DOR) and kappa-opioid receptor. Both the analgesic and reinforcing effects of opioids are mediated primarily by MOR, which is readily expressed on surface membrane of central neurons (Contet et al., 2004; Matthes et al., 1996; Waldhoer et al., 2004). In contrast, the function of DOR in opioid analgesia and opioid addiction remains elusive at present (Contet et al., 2004; Fields, 2004).

Membrane trafficking of G protein-coupled receptors (GPCRs) is a highly regulated dynamic process involved in neuronal adaptations to changing environmental stimuli in brain functions and in chronic diseases (Hanyaloglu and von Zastrow, 2008; Tan et al., 2004). Constitutively localized in intracellular compartments, DOR, a GPCR, normally lacks cellular effects in brain neurons, but translocates to surface membrane and becomes functional under various pathological conditions, including chronic opioid exposure, chronic pain, tissue inflammation and behavioral stress (Commons, 2003; Hack et al., 2005; Hurley and Hammond, 2000; Ma et al., 2006). Thus, DOR may play a more important role in neuronal adaptations to pathological conditions than in basal opioid functions in the brain. These findings of adaptive DOR translocation not only provide a unique platform for studying the neurobiological mechanisms of GPCR trafficking, but also serve as a valuable model for understanding of DOR functions in chronic opioid-related diseases such as drug dependence and drug addiction (Bie et al., 2010; Cahill et al., 2007). As the DOR trafficking occurs both in pain-modulating neurons in the brain

and spinal cord, and in drug reward-related amygdala neurons (Bie et al., 2009; Cahill et al., 2007; Ma et al., 2006), understanding how this newly emerged DOR signals via intracellular pathways to exert its cellular effects is important to reveal its significance in the pathogenesis of such chronic opioid-related diseases.

Opioid inhibition of GABAergic synaptic transmission is one of the main cellular mechanisms for opioid-induced analgesia (Fields, 2004; Pan et al., 1997). Previous studies have shown important roles of arachidonic acid (AA) metabolites in MOR-mediated GABA inhibition and analgesic effects under opioid-naïve conditions. In response to various pathologic stimuli including inflammatory cytokines, AA is released from phospholipids of cell membrane under regulation primarily by cytosolic phospholipase A2 (PLA2) and is converted to signaling molecules of eicosanoids through three main metabolic pathways of cyclooxygenase (COX), lipoxygenase (LOX) and epoxygenase/P450 (Harizi et al., 2008; Shimizu and Wolfe, 1990). The COX pathway is well known for generating inflammatory molecules prostaglandins whereas the LOX pathway mediates MOR inhibition of presynaptic GABA release in central neurons *in vitro* (Vaughan et al., 1997). A recent behavioral study *in vivo* shows that the MOR agonist morphine induces antinociception through the epoxygenase/P450 pathway (Conroy et al., 2010). However, under chronic opioid conditions, the signaling of these opioid receptors has yet to be characterized. We have shown recently that chronic opioid-induced new DOR produces inhibition of GABA synaptic transmission and an analgesic effect in a PLA2-dependent manner (Zhang and Pan, 2010). Nevertheless, the intracellular signaling pathways to which the emerged DOR couples to produce its cellular effects are largely unknown at present.

In this study with cellular recording of synaptic activities *in vitro* and system analysis of pain behaviors *in vivo*, we determined the detailed signaling cascades responsible for DOR inhibition of GABA neurotransmission and for DOR-mediated behavioral antinociception in brainstem neurons of the nucleus raphe magnus (NRM), an important supraspinal structure for opioid modulation of pain (Fields, 2004; Pan et al., 1997).

Materials and Methods

Animals and chronic morphine treatment. All procedures involving the use of animals conformed to the guidelines by the University of Texas MD Anderson Cancer Center Animal Care and Use Committee. Male Wistar rats were randomly divided into two groups: morphine group and saline or placebo control group, and were treated with chronic morphine or saline/placebo as described previously (Zhang and Pan, 2010). For whole-cell recordings, neonatal rats (9–14 days old) in the morphine group were injected (i.p.) with increasing doses of morphine twice daily for 6 days with the last morphine injection at around 5 PM on day 6. The morphine dose was 10 mg/kg on day 1 and was increased by 5 mg/kg each day to reach the maximum dose of 30 mg/kg on days 5 and 6. Rats in the saline group were similarly injected with saline for controls. The injection volume was 0.1 to 0.3 ml. Neonatal rats were used for whole-cell recording due to limited cell visibility and quality for visualized recording in NRM slices from older rats. Both similarities and differences are recognized between neonatal and adult rats in pain responses of NRM neurons for data interpretation (Zhang and Hammond, 2010). Nonetheless, we have successfully used findings of cellular recording from neonatal rats as a useful and efficient model with recognized limitations to help understand the cellular mechanisms of pain behavior in adult rats (Bie et al., 2005; Ma and Pan, 2006; Pan et al., 1997; Zhang et al., 2011; Zhang and Pan, 2010). For behavioral experiments, rats (200–300 g) in the morphine group were subcutaneously implanted with one morphine pellet (75 mg) on day 1 and two more morphine pellets on day 4. In the placebo group, rats were similarly implanted with placebo pellets. Experiments for whole-cell recordings and behavioral tests were performed on day 7. For chronic morphine treatment, the methods

of daily morphine injections in neonatal rats and pellet implantations in adult rats were selected primarily due to technical difficulties for pellet implantation in neonatal rats and too large an amount of morphine required for injections in adult rats. As shown in our previous studies, no detectable difference was observed between the two methods in terms of adaptive responses of NRM neurons and pain behaviors with our experimental protocols, as data were collected after the completion of the morphine treatments (Bie et al., 2005; Pan, 2003).

Brian slice preparations and whole-cell recording. The general methods of visualized whole-cell voltage-clamp recording have been described previously (Bie et al., 2005; Zhang and Pan, 2010). NRM slices (200 μm thick) were cut and a single slice was perfused in a recording chamber with preheated (35°C) physiological saline containing the following (in mM): 126 NaCl, 2.5 KCl, 1.2 NaH₂PO₄, 1.2 MgCl₂, 2.4 CaCl₂, 11 glucose, and 25 NaHCO₃, saturated with 95% O₂ and 5% CO₂, pH 7.2–7.4. Visualized whole-cell recordings were obtained from identified NRM neurons with a glass pipette (resistance, 3–5 M Ω) filled with a solution containing the following (in mM): 126 KCl, 10 NaCl, 1 MgCl₂, 11 EGTA, 10 HEPES, 2 ATP, and 0.25 GTP, pH adjusted to 7.3 with KOH; osmolarity, 280–290 mOsM. Electrical stimuli of constant current (0.25 ms, 0.2–0.4 mA) were used to evoke GABA-mediated inhibitory post-synaptic currents (IPSCs) with a bipolar stimulating electrode placed within the nucleus. With a KCl-filled pipette and a holding potential of –70 mV, GABA IPSCs were in an inward (downward) direction (Pan et al., 1990). GABA IPSCs were recorded in the presence of glutamate receptor antagonists D-(–)-2-amino-5-phosphonopentanoic acid (50 μM) and 6-cyano-7-nitroquinoxaline-2,3-dione (10 μM), and were completely blocked by GABA_A receptor

antagonist bicuculline (10 μ M). Miniature IPSCs were obtained in 60-s epochs in the presence of tetrodotoxin (1 μ M) and a sliding IPSC template custom-defined with the acquisition software was used to detect and analyze the frequency and amplitude of miniature IPSCs. Recordings were typically made 1–3 h after slice cutting and no morphine was added to the bath solution so that neurons in slices of the morphine group were likely under a condition of early withdrawal (Bie et al., 2005). We did not observe a time-dependent withdrawal effect on neuronal properties in our experimental conditions. Inhibitors NDGA (10 μ M), baicalein (10 μ M), AA-861 (10 μ M), indomethacin (10 μ M), miconazole (20 μ M) and PD146176 (10 μ M) were applied through the bath for at least 10 min before data collection. Ca^{++} channel inhibitors were administered through the bath 3 min before deltorphin application. The target effects of the abovementioned inhibitors at the concentration used have been reported in previous studies (Metea and Newman, 2006; Sendobry et al., 1997; Vaughan et al., 1997). At these inhibitor concentrations, no effect was observed on the amplitude of evoked IPSCs by the inhibitors themselves, nor was it reported previously.

Microinjection and behavioral experiments. NRM microinjection was performed as previously described (Ma et al., 2006; Zhang and Pan, 2010). A rat was implanted with a 26-gauge double-guide cannula (Plastics One, Roanoke, VA) aiming at the NRM (anteroposterior, –10.0 from the Bregma; lateral, 0; dorsoventral, –10.5 from the dura) (Kroon and Riley, 1986). Pain threshold was measured every 5 min by the tail-flick test on a freely moving rat with a Hargreaves analgesia instrument (Stoelting, Kiel, WI). The heat intensity was set to elicit stable baseline latencies with a cutoff time of 10 s. Drugs were microinjected into the NRM in a total volume of 0.4 μ l through a 33-gauge

double-injector with an infusion pump at a rate of 0.2 μ l/min. The confined effect of an injected drug within the NRM with this microinjection method has been demonstrated in our previous studies (Ma et al., 2006; Zhang and Pan, 2010). All NRM microinjection sites were histologically verified after the experiment by injecting a blue dye and controls of off-site injections were performed as shown before (Bie et al., 2005). Indomethacin was injected i.p. due to consideration of this widely used administration route in previous pain research and its known permeability through the blood-brain barrier. The behavioral effect of a microinjected inhibitor was measured 20–30 min after its administration.

Statistical analyses and materials. Numerical data of GABA IPSCs from control groups and treatment groups were statistically analyzed and compared with the Students' t test (paired or unpaired, two-tailed). Data are presented as means \pm standard error of the means. Behavioral results were statistically analyzed by an ANOVA for repeated measures and the Tukey–Kramer test of *post hoc* analysis. $P < 0.05$ was considered as statistically significant. Deltorphan, morphine sulfate, and morphine and placebo pellets were kindly supplied by the drug program of the National Institute on Drug Abuse (Bethesda, MD). All other drugs were purchased from Sigma-Aldrich or Tocris Bioscience (Ellisville, MO).

Results

Chronic morphine induces new functional DOR on presynaptic GABA

terminals. Under whole-cell voltage-clamp recording in brainstem slices *in vitro*, the selective DOR agonist deltorphin (1 μ M), ineffective in control neurons from saline-treated rats, inhibited the GABAergic inhibitory post-synaptic current (IPSC) in NRM neurons from morphine-treated rats; and the deltorphin inhibition was completely blocked by the DOR antagonist naltriben (10 μ M, Fig. 1A). This inhibition of evoked GABA IPSCs by chronic morphine-induced DOR is consistent with the results in our previous report (Zhang and Pan, 2010). We determined effects of the DOR on action potential-independent GABAergic miniature IPSCs (mIPSCs) to further identify the synaptic site of this DOR action. Deltorpin (1 μ M) significantly decreased the frequency, but not the amplitude, of mIPSCs in neurons (n = 10) from morphine-treated rats, but had no apparent effect on either the frequency or the amplitude of mIPSCs in neurons (n = 6) from saline-treated rats (Fig. 1, B and C). These results indicate that chronic morphine induces functional DOR on presynaptic GABA terminals and activation of this DOR inhibits presynaptic GABA release in NRM neurons.

The 12-LOX pathway mediates DOR inhibition of GABA IPSCs. Our recent study shows that inhibition of GABA IPSCs by the emerged DOR is dependent on both PLA2 and cAMP/protein kinase A (PKA) (Zhang and Pan, 2010). In NRM neurons from chronic morphine-treated rats, we investigated the detailed signaling cascades, downstream from PLA2, that were involved in the DOR inhibition of GABA synaptic transmission, focusing on the PLA2-regulated AA metabolic pathways. As illustrated in Fig. 2A, we used selective inhibitors to pharmacologically block each of the three major

AA signaling pathways of COX, LOX and epoxygenase/P450 in the following experiments on NRM neurons from morphine-treated rats. We have reported previously that AACOCF3 (10 μ M), a selective inhibitor of PLA2 that mediates the production of AA from membrane phospholipids (Harizi et al., 2008), significantly inhibits the deltorphin (1 μ M)-induced inhibition (to $53.6 \pm 5.6\%$ of control) of GABA IPSCs (Zhang and Pan, 2010). In the presence of the LOX inhibitor nordihydroguaiaretic acid (NDGA, 10 μ M) (Vaughan et al., 1997), we found that deltorphin inhibition of IPSCs was largely blocked (to $85.1 \pm 7.2\%$, $p < 0.01$, $n = 8$, Fig. 2, B and E). The remaining DOR inhibition in the presence of NDGA is likely mediated, at least partially, by the cAMP/PKA pathway as we showed before (Zhang and Pan, 2010). Blocking the epoxygenase/P450 pathway with the selective inhibitor miconazole (20 μ M) (Metea and Newman, 2006) did not significantly affect the deltorphin effect on IPSCs (to $60.8 \pm 7.8\%$, $p > 0.05$, $n = 8$, Fig. 2, C and E). In contrast to the blocking effect of NDGA, the COX inhibitor indomethacin (10 μ M) augmented the deltorphin effect, increasing the inhibition of IPSCs to $38.0 \pm 5.2\%$ ($p < 0.05$, $n = 7$, Fig. 2, D and E). Thus, it appears that the LOX pathway primarily mediates DOR inhibition of GABA synaptic release in these neurons.

Next, we determined which LOX subtype was mainly responsible for the DOR inhibition of IPSCs in NRM neurons from chronic morphine-treated rats. We found that blocking 12-LOX with baicalein (10 μ M) (Vaughan et al., 1997) significantly antagonized the deltorphin effect (to $81.3 \pm 10.3\%$, $p < 0.01$, $n = 8$, Fig. 3, A and F) whereas blockade of 15-LOX with PD146176 (10 μ M) (Sendobry et al., 1997) had no effect on the DOR inhibition (to $52.1 \pm 8.7\%$, $p > 0.05$, $n = 6$, Fig. 3, B and F). Similar to the indomethacin effect, the 5-LOX inhibitor AA-861 (10 μ M) (Vaughan et al., 1997)

also enhanced the deltorphin effect, increasing DOR inhibition of IPSCs to $35.2 \pm 2.8\%$ ($p < 0.05$, $n = 9$, Fig. 3, C and F). In addition, application of AA ($150 \mu\text{M}$) produced a significant inhibition on the IPSC amplitude in these neurons from morphine-treated rats (to $63.5 \pm 14.2\%$, $p < 0.01$, $n = 5$), which was mostly reversed by the 12-LOX inhibitor baicalein ($10 \mu\text{M}$, to $85.2 \pm 8.6\%$, $p < 0.05$, $n = 6$, Fig. 3, D and G). To further validate the involvement of 12-LOX in the DOR effect, we examined the effect of AA metabolites, hydroperoxyeicosatetraenoic acids (HPETEs) and hydroxyeicosatetraenoic acids (HETEs), converted by the three LOX subtypes (Fig. 2) (Harizi et al., 2008; Vaughan et al., 1997). Consistent with the above experiments using enzyme inhibitors, bath application of 12-HPETE (100 nM) significantly suppressed the IPSC amplitude to $65.0 \pm 4.5\%$ of control ($n = 8$, $p < 0.01$); in contrast, 5-HETE (100 nM) did not alter the IPSC amplitude ($n = 8$, $p > 0.05$), nor did 15-HPETE ($50 \mu\text{M}$, $n = 5$, $p > 0.05$) (Fig. 3. E and G).

Taken together, these results suggest that activation of chronic morphine-induced DOR on GABAergic terminals inhibits presynaptic GABA release through the PLA2–AA–12-LOX pathway. The DOR-facilitating effect of blocking COX and 5-LOX is presumably due to shunting of more endogenous AA metabolites to the 12-LOX pathway, thus augmenting the DOR effect.

Signaling pathway for MOR inhibition of GABA IPSCs. We have shown previously that the chronic morphine-induced DOR emerges on GABAergic terminals on which MOR is readily expressed in NRM neurons, producing functional synergism of DOR and MOR (Zhang and Pan, 2010). We examined the PLA2-dependent signaling pathways for MOR inhibition of GABA IPSCs under chronic morphine conditions. In

neurons from chronic morphine-treated rats, the selective MOR agonist DAMGO (1 μ M) inhibited the amplitude of GABA IPSCs to $47.9 \pm 4.3\%$ of control ($n = 16$, $p < 0.01$). This MOR inhibition was significantly antagonized by the 12-LOX inhibitor baicalein (10 μ M) (to $68.2 \pm 8.7\%$, $n = 8$, $p < 0.05$, Fig. 4). Interestingly, blockade of epoxygenases/P450 with miconazole (20 μ M) also significantly reduced the DAMGO inhibition (to $69.0 \pm 4.9\%$, $n = 8$, $p < 0.01$, Fig. 4). Similar to the DOR inhibition, the remaining MOR inhibition is likely mediated partially by the cAMP/PKA pathway (Zhang and Pan, 2010). Consistent with the indomethacin effect reported in a previous study under naive conditions (Vaughan et al., 1997), the COX inhibitor (10 μ M) enhanced the DAMGO inhibition of IPSCs in NRM neurons from chronic morphine-treated rats (data not shown). These results support the notion that, under chronic opioid conditions, both the 12-LOX and epoxygenase/P450 pathways mediate MOR inhibition of GABA synaptic transmission in these neurons. Thus, it appears that both DOR and MOR share the same 12-LOX pathway in their pre-synaptic inhibition of GABA synaptic transmission under chronic opioid conditions.

Involvement of Ca⁺⁺ channels in DOR inhibition of GABA IPSCs. We investigated whether Ca⁺⁺ channels, commonly involved in pre-synaptic neurotransmitter release (Catterall and Few, 2008), were involved in the DOR inhibition of GABA release. In slices from chronic morphine-treated rats, we found that deltorphin inhibition of GABA IPSCs was significantly reduced by pre-treatment of the slice with ω -conotoxin GVIA (0.5 μ M, Fig. 5), a selective N-type Ca⁺⁺ channel inhibitor (Andrade et al., 2010). In contrast, similar pre-treatment with the L-type Ca⁺⁺ channel inhibitor nifedipine (10 μ M) or the P/Q type Ca⁺⁺ channel inhibitor ω -agatoxin TK (0.2 μ M) (Momiya and

Fukazawa, 2007) failed to alter the deltorphin inhibition (Fig. 5). This indicates the involvement of N-type Ca^{++} channels in DOR inhibition of GABA release.

The 12-LOX pathway mediates DOR-induced antinociception. Inhibition of central GABA synaptic transmission, consequently causing disinhibition (or activation) of central pain-inhibiting neurons, is one of the main mechanisms for opioid-induced analgesia (Fields, 2004; Pan et al., 1997). Thus, activation of the emerged DOR in the NRM produces behavioral antinociception *in vivo* (Ma et al., 2006; Zhang and Pan, 2010). Based on the cellular results above, we hypothesized that the 12-LOX metabolic pathway was important for the DOR-induced antinociception. To demonstrate that, we conducted behavioral experiments with site-specific microinjections in chronic morphine-treated rats *in vivo*. A single microinjection of deltorphin (1 μg) into the NRM produced a significant antinociceptive effect in morphine-treated rats ($n = 5$ rats, Fig. 6A). We have shown that this deltorphin effect is blocked by co-microinjection of the DOR antagonist naltriben, suggesting a specific DOR-mediated effect (Ma et al., 2006; Pan et al., 1997). Consistent with our hypothesis, a pre-treatment with NRM microinjection of the LOX inhibitor NDGA (1 μg , $n = 5$) 1 h before deltorphin infusion blocked the deltorphin-induced antinociceptive effect ($n = 5$, Fig. 6B). In addition, the deltorphin effect was also significantly attenuated by a similar NRM pre-infusion of the 12-LOX inhibitor baicalein (1 μg $n = 5$, Fig. 6B). These findings provide behavioral evidence showing an important role of the 12-LOX signaling pathway in DOR-mediated antinociception under chronic opioid conditions.

Since blockade of the COX pathway or the 5-LOX pathway augmented DOR inhibition of GABA IPSCs, we reasoned that this pharmacological treatment should

enhance the DOR-mediated antinociceptive effect in chronic morphine-treated rats *in vivo*. As expected, we found that systemic administration of the COX inhibitor indomethacin (20 mg/kg, i.p., n = 5) 1 h before NRM microinjection of deltorphin significantly increased the deltorphin-induced antinociceptive effect, and so did NRM pre-infusion of the 5-LOX inhibitor AA-861 (1 μ g, n = 5, Fig. 7A). Consistent with its lack of effect on DOR inhibition of IPSCs, the epoxygenase/P450 inhibitor miconazole (1 μ g, n = 5) pre-infused into the NRM failed to alter the deltorphin antinociception (Fig. 7A). Finally, we determined whether this enhanced DOR antinociception by blocking 5-LOX or COX was dependent on the 12-LOX pathway. In morphine-treated rats, pre-treatment with NRM infusion of baicalein (1 μ g) plus indomethacin or AA-861 1 h before deltorphin microinjection nearly abolished the enhanced antinociceptive effect (n = 5 rats for each group, Fig. 7B). This further supports the notion that the enhanced DOR effect is likely due to shunting of AA metabolites from the COX pathway and the 5-LOX pathway to the 12-LOX pathway, which mediates the DOR antinociception.

Discussion

We have demonstrated cellular and behavioral evidence showing that the 12-LOX pathway functionally couples to the newly emerged DOR induced by chronic opioids and primarily mediates DOR inhibition of GABA synaptic transmission in NRM neurons, leading to a DOR-mediated antinociceptive effect *in vivo*. Interestingly, this 12-LOX pathway, shared by existing MOR on the same GABA terminals, is also involved in the augmentation of DOR-mediated antinociception by blocking the COX and 5-LOX pathways. Thus, the PLA2-AA-12-LOX cascade is a key signaling pathway for the cellular effect and behavioral antinociception of DOR as well as MOR under chronic opioid conditions.

Signaling of DOR and MOR. Opioid receptors couple to the release of AA from membrane phospholipids via a G protein-regulated, PLA2-mediated signal transduction pathway (Fukuda et al., 1996). The LOX pathway, or specifically 12-LOX, was first discovered to mediate MOR inhibition of presynaptic GABA release in midbrain periaqueductal gray neurons in naïve condition (Vaughan et al., 1997). Our previous study in central amygdala neurons suggests that MOR inhibition of presynaptic glutamate release is also mediated by a PLA2-regulated mechanism in normal conditions (Zhu and Pan, 2005). Under chronic opioid conditions, the present study shows that both the newly emerged DOR and existing MOR on GABAergic terminals couple to the PLA2-AA-12-LOX pathway, of which the metabolic product 12-HPETE and possibly other metabolites inhibit presynaptic GABA release directly or indirectly by opening the 4-aminopyridine-sensitive potassium channels (Vaughan et al., 1997; Zhu and Pan, 2005). Therefore, it appears that, while the MOR signaling remains unchanged after chronic opioid treatment,

the translocated DOR couples to the same signaling pathway as MOR on GABAergic terminals in NRM neurons. The current study also demonstrates that this DOR signaling is required for its antinociceptive effect *in vivo*. It should be noted that both the DOR inhibition and MOR inhibition of GABA IPSCs were partially blocked by inhibiting the 12-LOX pathway. As reported in our previous study (Zhang and Pan, 2010), the remaining inhibition is likely mediated, at least partially, by the cAMP/PKA pathway that also couples to the translocated DOR and is recruited to the MOR signaling by chronic opioids. In addition to the AA metabolite-gated potassium channels, our results indicate that DOR inhibition of pre-synaptic GABA release is also partially mediated by inhibition of the N-type Ca^{++} channel, a mechanism also shared by MOR inhibition of glutamate synaptic transmission in spinal neurons under naïve conditions (Heinke et al., 2011). It is also worth noting that our results were based on pharmacological inhibitors, which, while reasonably selective, have limits in selectivity for blockade of their intended targets. Alternative methods are warranted to further validate relative weight of the signaling pathways for the DOR effects.

An interesting topic related to receptor signaling is the heteromerization of opioid receptors and particularly, MOR–DOR heteromers. Recent evidence suggests that, in the rostroventral medulla that contains NRM, chronic morphine increases the abundance of MOR–DOR heteromers, which display altered properties in ligand binding, G-protein coupling and agonist-induced receptor activity (Rozenfeld and Devi, 2011). It is unknown whether MOR–DOR heteromerization occurs in NRM neurons after chronic morphine treatment under the experimental conditions of this study. In a preliminary study using functional analysis in NRM neurons, we found no significant changes in the

kinetics and potency of MOR and DOR agonist-induced inhibition of presynaptic GABA synaptic release and activation of postsynaptic potassium channels after chronic morphine treatment (Pan et al., unpublished observations). Further studies with various functional assays are necessary to detect potential MOR–DOR heteromers and examine their signaling properties in the brainstem neurons.

Interaction of AA signaling pathways. Since chronic opioid-induced DOR appears on MOR-expressing GABA terminals and both opioid receptors share the same 12-LOX pathway, understanding of the functional interaction between DOR and MOR and among the AA signaling pathways is important to reveal the adaptive role of DOR in opioid analgesia under chronic opioid conditions where analgesic tolerance occurs to MOR agonists. Our observation that blockade of 5-LOX as well as COX, but not 15-LOX or epoxygenases/P450, enhanced both the synaptic and behavioral effects of DOR may indicate that the AA–12-LOX, AA–5-LOX and AA–COX pathways are metabolically more active or dominant than the AA–epoxygenase/P450 and AA–15-LOX pathways so that blocking 5-LOX or COX pathways shunts AA metabolites to the 12-LOX pathway, therefore enhancing the DOR effects. The ineffectiveness of blocking 15-LOX or epoxygenases/P450 on the DOR effects may reflect low metabolic activity of these two pathways in the DOR-coupled AA metabolism. This is consistent with AA metabolic activities coupled to MOR in naïve conditions (Vaughan et al., 1997).

The role of epoxygenases/P450 in the signaling and function of opioid receptors is just emerging. A recent behavioral study using transgenic mice shows that genetic reduction in P450 activity partially blocks analgesia induced by morphine, a primarily MOR agonist (Conroy et al., 2010). However, the underlying cellular mechanisms are

unknown. The present results in NRM neurons provide synaptic evidence for the epoxygenase/P450 involvement in MOR inhibition of GABA IPSCs, an opioid effect that accounts for opioid-induced behavioral analgesia (Fields, 2004; Pan et al., 1997). Interestingly, our data also show that the synaptic signaling of emerged DOR, in contrast to MOR, does not appear to involve the epoxygenase/P450 pathway, perhaps representing some differences in the DOR and MOR signaling in regulation of GABA release.

Behavioral significance of DOR signaling. In addition to identifying the 12-LOX pathway responsible for the synaptic action of DOR, the present study also provides evidence for the behavioral significance of this DOR signaling in DOR-mediated antinociception in animals. Thus, DOR signaling through the AA-12-LOX pathway appears to mainly mediate DOR-induced antinociceptive effect, supporting the synaptic inhibition of GABA release by DOR through the same pathway as a likely underlying mechanism for DOR inhibition of pain. The analgesic effects of non-steroidal anti-inflammatory drugs, primarily COX inhibitors such as aspirin and indomethacin, are well documented and have been partially attributed to their shunting of endogenous AA metabolites from the COX pathway to the 12-LOX pathway (Williams, 1997). However, whether 5-LOX inhibitors, which also enhance synaptic effects of opioids as shown in this study, are behaviorally analgesic has not been demonstrated. The current study shows that blocking 5-LOX produces a significant augmentation of the DOR-mediated antinociceptive effect that is at least equally potent to the augmentation by blocking COX in chronic opioid conditions. Furthermore, both of the two analgesia-augmenting effects of 5-LOX and COX inhibitors are sensitive to 12-LOX inhibitors, further supporting the

notion that the augmentation is at least partly due to shunting of AA metabolites to the 12-LOX pathway.

In summary, the present study has identified the PLA₂–AA–12-LOX pathway as a primary signaling cascade for chronic opioid-induced DOR inhibition of GABA synaptic transmission and consequently, DOR-mediated antinociceptive effect. It also suggests that the combination of DOR-induced 12-LOX metabolites and 5-LOX inhibitors may serve as a promising therapeutic strategy in long-term opioid treatment of chronic pain that has been tolerant to conventional MOR-based analgesics.

Authorship contributions

Participated in research designs: Zhang and Pan

Conducted experiments: Zhang

Performed data analysis: Zhang and Pan

Wrote or contributed to the writing of the manuscript: Zhang and Pan

References

- Andrade A, Denome S, Jiang YQ, Marangoudakis S, and Lipscombe D (2010) Opioid inhibition of N-type Ca²⁺ channels and spinal analgesia couple to alternative splicing. *Nat Neurosci* **13**:1249-1256.
- Bie B, Peng Y, Zhang Y, and Pan ZZ (2005) cAMP-mediated mechanisms for pain sensitization during opioid withdrawal. *J Neurosci* **25**:3824-3832.
- Bie B, Zhang Z, Cai YQ, Zhu W, Zhang Y, Dai J, Lowenstein CJ, Weinman EJ, and Pan ZZ (2010) Nerve growth factor-regulated emergence of functional delta-opioid receptors. *J Neurosci* **30**:5617-5628.
- Bie B, Zhu W, and Pan ZZ (2009) Rewarding morphine-induced synaptic function of delta-opioid receptors on central glutamate synapses. *J Pharmacol Exp Ther* **329**:290-296.
- Cahill CM, Holdridge SV, and Morinville A (2007) Trafficking of delta-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia. *Trends Pharmacol Sci* **28**:23-31.
- Catterall WA, and Few AP (2008) Calcium channel regulation and presynaptic plasticity. *Neuron* **59**:882-901.
- Commons KG (2003) Translocation of presynaptic delta opioid receptors in the ventrolateral periaqueductal gray after swim stress. *J Comp Neurol* **464**:197-207.
- Conroy JL, Fang C, Gu J, Zeitlin SO, Yang W, Yang J, VanAlstine MA, Nalwalk JW, Albrecht PJ, Mazurkiewicz JE, Snyder-Keller A, Shan Z, Zhang SZ, Wentland MP, Behr M, Knapp BI, Bidlack JM, Zuiderveld OP, Leurs R, Ding X, and

- Hough LB (2010) Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. *Nat Neurosci* **13**:284-286.
- Contet C, Kieffer BL, and Befort K (2004) Mu opioid receptor: a gateway to drug addiction. *Curr Opin Neurobiol* **14**:370-378.
- Fields H (2004) State-dependent opioid control of pain. *Nat Rev Neurosci* **5**:565-575.
- Fukuda K, Kato S, Morikawa H, Shoda T, and Mori K (1996) Functional coupling of the delta-, mu-, and kappa-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells. *J Neurochem* **67**:1309-1316.
- Hack SP, Bagley EE, Chieng BC, and Christie MJ (2005) Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment. *J Neurosci* **25**:3192-3198.
- Hanyaloglu AC, and von Zastrow M (2008) Regulation of GPCRs by endocytic membrane trafficking and its potential implications. *Annu Rev Pharmacol Toxicol* **48**:537-568.
- Harizi H, Corcuff JB, and Gualde N (2008) Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. *Trends Mol Med* **14**:461-469.
- Heinke B, Gingl E, and Sandkuhler J (2011) Multiple targets of mu-opioid receptor-mediated presynaptic inhibition at primary afferent Adelta- and C-fibers. *J Neurosci* **31**:1313-1322.
- Hurley RW, and Hammond DL (2000) The analgesic effects of supraspinal mu and delta opioid receptor agonists are potentiated during persistent inflammation. *J Neurosci* **20**:1249-1259.

- Kroon JP, and Riley AL (1986) A microcomputer-based system for stereotaxic coordinates in the rat brain. *Physiol Behav* **38**:593-596.
- Ma J, and Pan ZZ (2006) Contribution of brainstem GABA(A) synaptic transmission to morphine analgesic tolerance. *Pain* **122**:163-173.
- Ma J, Zhang Y, Kalyuzhny AE, and Pan ZZ (2006) Emergence of functional delta-opioid receptors induced by long-term treatment with morphine. *Mol Pharmacol* **69**:1137-1145.
- Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, and Kieffer BL (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. *Nature* **383**:819-823.
- Metaa MR, and Newman EA (2006) Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling. *J Neurosci* **26**:2862-2870.
- Momiyama T, and Fukazawa Y (2007) D1-like dopamine receptors selectively block P/Q-type calcium channels to reduce glutamate release onto cholinergic basal forebrain neurones of immature rats. *J Physiol* **580**:103-117.
- Pan ZZ (2003) Opioid tolerance in adult and neonatal rats. *Methods Mol Med* **84**:223-232.
- Pan ZZ, Tershner SA, and Fields HL (1997) Cellular mechanism for anti-analgesic action of agonists of the kappa-opioid receptor. *Nature* **389**:382-385.
- Pan ZZ, Williams JT, and Osborne PB (1990) Opioid actions on single nucleus raphe magnus neurons from rat and guinea-pig in vitro. *J Physiol* **427**:519-532.

- Rozenfeld R, and Devi LA (2011) Exploring a role for heteromerization in GPCR signalling specificity. *Biochem J* **433**:11-18.
- Sendobry SM, Cornicelli JA, Welch K, Bocan T, Tait B, Trivedi BK, Colbry N, Dyer RD, Feinmark SJ, and Daugherty A (1997) Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. *Br J Pharmacol* **120**:1199-1206.
- Shimizu T, and Wolfe LS (1990) Arachidonic acid cascade and signal transduction. *J Neurochem* **55**:1-15.
- Tan CM, Brady AE, Nickols HH, Wang Q, and Limbird LE (2004) Membrane trafficking of G protein-coupled receptors. *Annu Rev Pharmacol Toxicol* **44**:559-609.
- Vaughan CW, Ingram SL, Connor MA, and Christie MJ (1997) How opioids inhibit GABA-mediated neurotransmission. *Nature* **390**:611-614.
- Waldhoer M, Bartlett SE, and Whistler JL (2004) Opioid receptors. *Annu Rev Biochem* **73**:953-990.
- Williams JT (1997) The painless synergism of aspirin and opium. *Nature* **390**:557, 559.
- Woolf CJ, and Hashmi M (2004) Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. *Curr Opin Investig Drugs* **5**:61-66.
- Zhang L, and Hammond DL (2010) Cellular basis for opioid potentiation in the rostral ventromedial medulla of rats with persistent inflammatory nociception. *Pain* **149**:107-116.
- Zhang Z, Cai YQ, Zou F, Bie B, and Pan ZZ (2011) Epigenetic suppression of GAD65 expression mediates persistent pain. *Nat Med* **17**:1448-1455.

Zhang Z, and Pan ZZ (2010) Synaptic mechanism for functional synergism between delta- and mu-opioid receptors. *J Neurosci* **30**:4735-4745.

Zhu W, and Pan ZZ (2005) Mu-opioid-mediated inhibition of glutamate synaptic transmission in rat central amygdala neurons. *Neuroscience* **133**:97-103.

Footnotes

This work was supported by the Nations Institutes of Health National Institute on Drug Abuse [Grants DA023069, DA027541].

Reprints requests should be sent to: Zhizhong Pan, Department of Anesthesiology and Pain Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Email: zzpan@mdanderson.org.

Legends for Figures

Fig. 1. Chronic morphine-induced delta-opioid receptor (DOR) inhibits GABA synaptic transmission by reducing pre-synaptic GABA release. A, Representative GABAergic inhibitory post-synaptic currents (IPSCs) in the absence (control) and presence of the selective DOR agonist deltorphin (1 μ M) in neurons of the nucleus raphe magnus (NRM) from a saline-treated rat and a morphine-treated rat without and with addition of the DOR antagonist naltriben (10 μ M). On average, deltorphin inhibited the GABA IPSCs to $53.6 \pm 5.6\%$ of control in neurons ($n = 15$) from morphine-treated rats (from Zhang and Pan, 2010). B, Representative current traces of miniature IPSCs with and without deltorphin in an NRM neuron from a saline- and a morphine-treated rat. C, Summarized data of deltorphin effects on the frequency and amplitude of miniature IPSCs in neurons of the saline (sal) group ($n=6$) and of the morphine (mor) group ($n=10$). * $p < 0.05$.

Fig. 2. DOR inhibition of GABA synaptic transmission is mediated by the lipoxygenase (LOX) pathway. A, Signaling pathways of arachidonic acid (AA) metabolism. Drug names following an X indicate the selective inhibitor that blocks that specific metabolic pathway. The thicker arrows depict relatively more dominant pathways involved in DOR-mediated effects (see Results for details). B–D, Representative GABA IPSCs in control and in deltorphin (1 μ M) in NRM slices from morphine-treated rats and pre-treated *in vitro* by bath application of the LOX inhibitor NDGA (10 μ M, B), the epoxygenase/P450 inhibitor miconazole (20 μ M, C) or the cyclooxygenase (COX) inhibitor indomethacin (10 μ M, D) for 10-15 min. E, Normalized effects of the indicated inhibitors on deltorphin

inhibition of GABA IPSCs in NRM neurons of the morphine group. N = 6–9 cells for each group. * $p < 0.05$, ** $p < 0.01$.

Fig. 3. The 12-LOX pathway mediates DOR inhibition of GABA synaptic transmission. A–C, Representative GABA IPSCs in control and in deltorphin in the presence of the 12-LOX inhibitor baicalein (10 μM , A), the 15-LOX inhibitor PD146176 (10 μM , B) or the 5-LOX inhibitor AA-861 (10 μM , C). D, GABA IPSCs in control and in the presence of AA (150 μM) or AA plus baicalein (10 μM). E, GABA IPSCs in control and in the presence of 12(S)-HPETE (100 nM), (\pm)5-HETE (100 nM) or 15(S)-HPETE (5 μM). F and G, Summarized data of deltorphin effects shown in A–C (F) and effects of AA metabolites shown in D and E (G) on GABA IPSCs in the absence and presence of the indicated inhibitors. N = 5–8 cells for each group. * $p < 0.05$, ** $p < 0.01$.

Fig. 4. Both the 12-LOX and epoxygenase/P450 pathways mediate the inhibition of GABA synaptic transmission by the mu-opioid receptor (MOR) under chronic opioid conditions. A, Effects of the selective MOR agonist DAMGO (1 μM) on GABA IPSCs in the absence (normal) and presence of baicalein (10 μM) or miconazole (20 μM) in NRM neurons from morphine-treated rats. B, Summarized data of the effects of DAMGO and the indicated inhibitors on GABA IPSCs. N = 8–16 cells for each group. * $p < 0.05$, ** $p < 0.01$.

Fig. 5. DOR inhibition of GABA neurotransmission involves the N-type Ca^{++} channel. A, Representative GABA IPSCs in control and in deltorphin (1 μM) in NRM neurons in


slices from morphine-treated rats and pre-treated *in vitro* with the N-type Ca⁺⁺ channel inhibitor ω -conotoxin GVIA (0.5 μ M), the L-type Ca⁺⁺ channel inhibitor nifedipine (10 μ M) or the P/Q-type Ca⁺⁺ channel inhibitor ω -agatoxin TK (0.2 μ M). B, Normalized effects of ω -conotoxin GVIA (n = 8 cells), nifedipine (n = 10) and ω -agatoxin TK (n = 5) on deltorphin inhibition of GABA IPSCs (n = 7) in slices as in A. ** $p < 0.01$.


Fig. 6. The 12-LOX pathway is involved in DOR-mediated antinociception *in vivo*. A, Effects of a single microinjection (arrow) of saline (n = 5 rats) or deltorphin (1 μ g, n = 5 rats) into the NRM on pain threshold measured by the tail-flick test in chronic morphine-treated rats *in vivo*. B, Antagonizing effect of a pre-treatment (1 h before) with NRM microinjection of the LOX inhibitor NDGA (1 μ g, n = 5 rats) or the 12-LOX inhibitor baicalein (1 μ g, n = 5 rats) on the deltorphin-induced antinociception. * and # depict statistical significance of the NDGA group and the baicalein group, respectively, when compared to the group of deltorphin alone. * and # $p < 0.05$, ** and ## $p < 0.01$.

Fig. 7. Inhibition of COX or 5-LOX augments DOR-mediated antinociception through 12-LOX. A, Behavioral effects of a pre-treatment (1 h before) with indomethacin (20 mg/kg, i.p., n = 5 rats) or with NRM microinjection of AA-861 (1 μ g, n = 5 rats) or miconazole (1 μ g, n = 5 rats) on the deltorphin-induced antinociception. * and # depict statistical significance of the AA-861 group and the indomethacin group, respectively, when compared to the group of deltorphin alone. B, Behavioral effects of baicalein (1 μ g) by NRM co-microinjection on facilitatory interaction in the antinociception induced by NRM microinjection of deltorphin plus AA-861 (1 μ g) or deltorphin plus indomethacin

(indom, 20 mg/kg, i.p.). N = 5 rats for each group. * depicts statistical significance for comparisons between the two groups of deltorphin plus AA-861 without and with baicalein; and # depicts results of statistical comparisons between the two groups of deltorphin plus indomethacin without and with baicalein. The arrows indicate NRM microinjection. # $p < 0.05$, ** and ## $p < 0.01$.

Figure 1





Molecular Pharmacology Fast Forward. Published on December 5, 2011 as DOI: 10.1124/mol.111.076
X AA861 has not been copyedited and formatted. The final version may differ from this version.

Figure 3




Figure 4




Figure 5





Figure 6






Figure 7

A



B

